Combination of anti-VEGF therapy and temozolomide in two experimental human glioma models

By Grossman Rachel   Brastianos Harry   Blakeley Jaishri   Mangraviti Antonella   Lal Bachchu   Zadnik Patti   Hwang Lee   Wicks Robert   Goodwin Rory   Brem Henry   Tyler Betty  

Journal of Neuro-Oncology, Vol. 116, Iss. 1, 2014-01 ,pp. : 59-65

Springer Publishing Company

Access to resources Recommend Favorite

Targeting Vascular Endothelial Growth Factor (VEGF) for Anti-tumor Therapy, by Anti-VEGF Neutralizing Monoclonal Antibodies or by VEGF Receptor Tyrosine-kinase Inhibitors

By Schlaeppi J-M.  

Cancer and Metastasis Reviews, Vol. 18, Iss. 4, 1999-12 ,pp. : 473-481

Springer Publishing Company

Access to resources Recommend Favorite

Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis

By  

Current Cancer Therapy Reviews, Vol. 7, Iss. 4, 2011-11 ,pp. : 282-289

Bentham Science Publishers

Access to resources Recommend Favorite

From Proteins to Nucleic Acid-Based Drugs: The Role of Biotech in Anti-VEGF Therapy

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 6, Iss. 4, 2006-01 ,pp. : 287-301

Bentham Science Publishers

Access to resources Recommend Favorite

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients

By Osada Takuya   Chong Gabriel   Tansik Robert   Hong Timothy   Spector Neil   Kumar Rakesh   Hurwitz Herbert   Dev Inderjit   Nixon Andrew   Lyerly H.   Clay Timothy   Morse Michael  

Cancer Immunology, Immunotherapy, Vol. 57, Iss. 8, 2008-08 ,pp. : 1115-1124

Springer Publishing Company

Access to resources Recommend Favorite